Cemiplimab plus imiquimod and laser before surgery for basal cell carcinoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests combining a skin cream (imiquimod), a laser treatment, and an immunotherapy drug (cemiplimab) before surgery for high-risk basal cell carcinoma. The goal is to see if this combination shrinks tumors enough to make surgery less disfiguring or damaging to nearby functions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of basal cell carcinoma that is considered high-risk and can be removed by surgery.
- Your tumor must be at least 2 cm (about 0.8 inches) on your trunk or arms/legs, or any size on your head, neck, hands, feet, or genital area.
- You must be well enough to perform daily activities (ECOG 0 or 1) and have a life expectancy of at least 24 weeks (about 6 months).
- You must not have had systemic cancer treatment (including immunotherapy) within the last 3 months or 5 half-lives (whichever is longer).
- You must not have an active autoimmune disease or a condition requiring high-dose steroids or other immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
This Phase 1 trial tests the drug cemiplimab given before and after surgery to reduce the chance that high-risk cutaneous squamous cell cancer comes back. You may be a candidate if your cancer is high-risk on pathology or imaging and is planned for surgical removal.
This trial tests a drug (cemiplimab) injected directly into early-stage skin cancer (squamous cell carcinoma) to see if it can shrink or cure the cancer before surgery. It may help patients avoid more extensive surgery or reduce the chance of the cancer coming back.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (EGFR inhibitor)—given before surgery for locally advanced squamous cell skin cancer. The goal is to shrink the tumor enough to make surgery safer and more effective.
This trial tests if giving a combination of two immunotherapy drugs (nivolumab and relatlimab) before surgery works better than one drug alone for people with large or high-risk basal cell skin cancer that needs surgery. The goal is to shrink the cancer and make surgery easier.
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
Hear when a new Cutaneous Basal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.